Simulations Plus Notes and Loans Receivable 2012-2026 | SLP
Simulations Plus notes and loans receivable from 2012 to 2026. Notes and loans receivable can be defined as current receivables created by lending money through notes and loans to third parties with maturities of less than 1 year, or a portion due in less than 1 year. This figure is captured at net value. If a gross value is given (primarily for loans receivable) the calculated allowance for uncollectable amounts is captured as well.
|
Simulations Plus Annual Notes and Loans Receivable (Millions of US $) |
|
|---|---|
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |
| 2013 | |
| 2012 | |
| 2011 | |
|
Simulations Plus Quarterly Notes and Loans Receivable (Millions of US $) |
|
|---|---|
| 2025-11-30 | |
| 2025-08-31 | |
| 2025-05-31 | |
| 2025-02-28 | |
| 2024-11-30 | |
| 2024-08-31 | |
| 2024-05-31 | |
| 2024-02-29 | |
| 2023-11-30 | |
| 2023-08-31 | |
| 2023-05-31 | |
| 2023-02-28 | |
| 2022-11-30 | |
| 2022-08-31 | |
| 2022-05-31 | |
| 2022-02-28 | |
| 2021-11-30 | |
| 2021-08-31 | |
| 2021-05-31 | |
| 2021-02-28 | |
| 2020-11-30 | |
| 2020-08-31 | |
| 2020-05-31 | |
| 2020-02-29 | |
| 2019-11-30 | |
| 2019-08-31 | |
| 2019-05-31 | |
| 2019-02-28 | |
| 2018-11-30 | |
| 2018-08-31 | |
| 2018-05-31 | |
| 2018-02-28 | |
| 2017-11-30 | |
| 2017-08-31 | |
| 2017-05-31 | |
| 2017-02-28 | |
| 2016-11-30 | |
| 2016-08-31 | |
| 2016-05-31 | |
| 2016-02-29 | |
| 2015-11-30 | |
| 2015-08-31 | |
| 2015-05-31 | |
| 2015-02-28 | |
| 2014-11-30 | |
| 2014-08-31 | |
| 2014-05-31 | |
| 2014-02-28 | |
| 2013-11-30 | |
| 2013-08-31 | |
| 2013-05-31 | |
| 2013-02-28 | |
| 2012-11-30 | |
| 2012-08-31 | |
| 2012-05-31 | |
| 2012-02-29 | |
| 2011-11-30 | |
| 2011-08-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Computer and Technology | Computer Software | $0.263B | $0.079B |
| Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Microsoft (MSFT) | United States | $2753.943B | 24.11 |
| Oracle (ORCL) | United States | $397.153B | 23.29 |
| SAP SE (SAP) | Germany | $200.369B | 23.43 |
| Intuit (INTU) | United States | $97.052B | 20.83 |
| Adobe (ADBE) | United States | $91.086B | 12.68 |
| Synopsys (SNPS) | United States | $75.138B | 41.38 |
| Cadence Design Systems (CDNS) | United States | $73.347B | 48.30 |
| Dassault Systemes SA (DASTY) | France | $26.551B | 15.11 |
| SS&C Technologies Holdings (SSNC) | United States | $16.192B | 12.48 |
| PTC (PTC) | United States | $15.879B | 17.91 |
| Manhattan Associates (MANH) | United States | $7.161B | 34.05 |
| Pegasystems (PEGA) | United States | $6.655B | 28.74 |
| Descartes Systems Group (DSGX) | Canada | $5.426B | 33.91 |
| Open Text (OTEX) | Canada | $5.117B | 5.65 |
| Trend Micro (TMICY) | Japan | $4.192B | 18.33 |
| ACI Worldwide (ACIW) | United States | $4.058B | 17.19 |
| CommVault Systems (CVLT) | United States | $3.908B | 37.98 |
| Sapiens (SPNS) | Israel | $2.433B | 31.04 |
| Blackbaud (BLKB) | United States | $1.574B | 12.02 |
| PROS Holdings (PRO) | United States | $1.123B | 0.00 |
| Progress Software (PRGS) | United States | $1.121B | 5.56 |
| Rand Worldwide (RWWI) | United States | $0.506B | 0.00 |
| OptimizeRx (OPRX) | United States | $0.115B | 9.15 |
| NetSol Technologies (NTWK) | United States | $0.040B | 21.06 |
| Neonode (NEON) | Sweden | $0.024B | 0.00 |
| Smith Micro Software (SMSI) | United States | $0.018B | 0.00 |
| Wetouch Technology (WETH) | China | $0.016B | 2.21 |
| Global Interactive Technologies (GITS) | South Korea | $0.009B | 0.00 |
| Magic Software Enterprises (MGIC) | Israel | $0.000B | 18.90 |